H1N1 Vaccine Trials: NIH Will Mix And Match Antigens, Adjuvants

The National Institutes of Health is developing a plan B as H1N1 vaccine manufacturers race to produce enough product by the start of flu season. The agency is going to mix and match antigen and adjuvant from different sponsors to try to find the best immunogenicity